Resolve Therapeutics
PrivateLast Round
Series B
Nov 1, 2012
Total Funding Raised
$7.8M
Company Overview
Resolve Therapeutics is a biotechnology company that develops non-immunosuppressive biologic therapies for the treatment of autoimmune diseases such as lupus and Sjögren's syndrome.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Resolve Therapeutics Comparables
Compare Resolve Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bristol Myers Squibb | 79% | |
| Rise Therapeutics | 70% | |
| Novartis | 67% |
Resolve Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 1, 2012 | ||||
| Series A | May 17, 2011 |
Resolve Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Washington Research Foundation Capital | Series B |
| Easton-Hunt Capital Partners, L.P. | Series B, Series A |
| New Science Ventures | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 1, 2012
$6M round led by New Science Ventures.
- May 17, 2011
$2M round led by Easton-Hunt Capital Partners and New Science Ventures.
Recent news
Latest coverage and updates
- is_developingOct 21, 2026
Resolve Therapeutics, LLC is developing nuclease therapy as a new approach to acute ischemic stroke, with preclinical data supporting the evaluation of RSLV-132 and RSLV-145.
- attends_eventOct 21, 2026
Resolve Therapeutics, LLC attends the 18th World Stroke Congress in South Korea from Oct 21st–23rd '26 and presents two e-posters featuring preclinical data on RSLV-132 and RSLV-145.
Resolve Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Resolve Therapeutics's valuation, stock price, and market status.
Is Resolve Therapeutics a public or private company?
Resolve Therapeutics is a private company.
What is the current stock price of Resolve Therapeutics?
Resolve Therapeutics is a private company, so its shares have no public market price. Caplight tracks Resolve Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Resolve Therapeutics worth (valuation)?
Valuation information for Resolve Therapeutics is not publicly available.
Can I buy Resolve Therapeutics stock?
Resolve Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Resolve Therapeutics's last funding round?
Resolve Therapeutics's most recent funding round was Series B on November 1, 2012.
Who are the main investors in Resolve Therapeutics?
Key investors in Resolve Therapeutics include New Science Ventures.
Will Resolve Therapeutics IPO soon?
No public IPO plans have been announced for Resolve Therapeutics.
How can I track Resolve Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Resolve Therapeutics's shares on secondary markets.